Log in
Metformin is now the most prescribed medication for type 2 diabetes worldwide. Pre - 1990 it received trivial use and was on the verge of withdrawal. Research at Aston (1993 - 1996) generated a new appreciation of its mechanisms of action and therapeutic potential. Aston research was reinforced with a concerted education programme for healthcare professionals, including high-profile reviews and treatment guidelines. We claim impact on health & welfare and health practitioners as Aston research has provided a foundation for improved care of type 2 diabetes patients on a global scale.
Advanced technologies for data visualisation and data mining, developed in the Unit in collaboration with national and international teams, are widely applied for development of medical services. In particular, a system for canine lymphoma diagnosis and monitoring developed with [text removed for publication] has now been successfully tested using clinical data from several veterinary clinics. The risk maps produced by our technology provide early diagnosis of lymphoma several weeks before the clinical symptoms develop. [text removed for publication] has estimated the treatment test, named [text removed for publication], developed with the Unit to add [text removed for publication] to the value of their business. Institute Curie (Paris), applies this data mapping technique and the software that has been developed jointly with Leicester in clinical projects.
Written and performed by Oliver Double, the stand-up comedy performance Saint Pancreas uses the medium of comedy to enhance public understanding of type 1 diabetes, and to challenge prevailing assumptions about the condition within and beyond the community of patients and their families. As a live performance and on DVD, the work has had impact on:
Furthermore, within the field of stand-up comedy itself, it has contributed to challenging and broadening the aesthetic possibilities of the form.
In 2003, researchers at the University of Dundee identified the tumour suppressor LKB1 as a critical upstream activator of AMP-activated protein kinase (AMPK), which provided the first link between AMPK and cancer. Metformin, the front-line therapy for type-2 diabetes, was already known to exert its beneficial effects through AMPK. An interdisciplinary collaboration at the University examined the link between metformin and cancer, and reported in 2005 that diabetics taking metformin had a reduced incidence of cancer. The impact has been clinical trials worldwide testing the benefit of metformin for cancer treatment, and development of therapeutics by pharmaceutical companies targeting this pathway.
Dr Lloyd's research examines the relationship between diabetes and mental health, particularly in under-served or marginalised communities. Through extensive international collaborations research findings have been disseminated to a wide audience. Locally, service users have been involved in the development of alternative ways of obtaining informed consent, to allow greater research inclusivity. Culturally appropriate tools, for identifying depressive symptoms as well as knowledge deficits in diabetes self-care, have been designed and tested. As a result, a psychotherapy service for people with co-morbid diabetes and psychological problems has been successfully established in a diabetes centre attended by more than 6,000 individuals.
This case study describes two types of impact. First, awareness of a health benefit has been raised in the treatment of people with diabetes, second, people with diabetes' attitudes to the treatment of diabetes has changed. These impacts were achieved in collaboration with health professionals working for two NHS trusts (Western Sussex Hospitals NHS Trust and Sussex Community NHS Trust) through the development of new educational materials to increase people with diabetes' awareness of diabetes and diabetes self-care behaviour.
More than half of UK adults aged over 45 years have high cholesterol levels, the major modifiable risk factor for cardiovascular disease (CVD). Over the past 20 years, University of Glasgow researchers have led numerous landmark clinical trials establishing the benefits of statins for CVD prevention. High-profile international clinical guidelines on lipid lowering cite these studies in the key evidence base for recommendations to guide statin use, demonstrating the considerable influence this work exerts on current clinical practice and public health. This has driven the global uptake of statins and provided the evidence-base for CVD risk assessment and prevention strategies that are now implemented worldwide. The use of statins has transformed patient care, provided a cost-effective prevention strategy for healthcare providers and made major contributions to the falling CVD mortality rates across Europe and the US.